DNA Script expanded on-demand DNA synthesis access in India through a distribution agreement with Imperial Life Sciences. Under the deal, ILS will distribute DNA Script’s SYNTAX platform across India, providing local sales, technical support, and application expertise to laboratories that want faster access to single-stranded DNA oligonucleotides. DNA Script positions SYNTAX as enabling benchtop enzymatic DNA synthesis with synthesis, purification, and normalization in one automated workflow. The company said the approach reduces dependence on overseas supply chains and helps shorten design-build-test cycles. The announcement reflects broader momentum toward decentralized lab production, which can be especially valuable for teams running iterative RNA/DNA experiments, assay development, and engineering workflows that depend on rapid oligo turnaround. With India emerging as a fast-growing life sciences market, the partnership targets adoption at scale rather than isolated pilot usage.